UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
|
|
|
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices, and Zip Code)
(
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act.
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
|
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective December 4, 2019, the Board of Directors (the “Board”) of AtriCure, Inc. (the “Company”) appointed Karen Prange and Daniel Florin to serve as Directors until the next Annual Meeting of Stockholders. The Board has determined that Ms. Prange and Mr. Florin are independent directors in accordance with guidelines that the Company has adopted, which also comply with the listing standards set forth by The NASDAQ Stock Market.
Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein (Nasdaq: HSIC), where she led a business that generated over $6 billion of revenue across three different business units and was a member of the Executive Committee. Ms. Prange’s service with Henry Schein began in 2016 and ended in April 2018. Prior to her role at Henry Schein, she led the Urology and Pelvic Health business for Boston Scientific, Inc. (NYSE: BSX) from 2012 to 2016, and held various positions of increasing responsibility for 17 years at Johnson & Johnson (NYSE: JMJ), most recently as General Manager of the Micrus Endovascular and Codman Neurovascular businesses.
Mr. Florin is currently Executive Vice President at Zimmer Biomet Holdings (NYSE: ZBH), a position to which he was appointed in July 2019 upon announcing his intention to retire from the company. Previously, he served as Executive Vice President and Chief Financial Officer of the company since June 2015. In addition, he served as Interim Chief Executive Officer of the company from July 2017 to December 2017. Prior to Zimmer’s merger with Biomet, Mr. Florin served as Senior Vice President and Chief Financial Officer of Biomet from June 2007 to June 2015. Before joining Biomet, Mr. Florin held various roles at Boston Scientific, Inc., CR Bard, Inc. and Deloitte & Touche, LLP.
There is no arrangement or understanding between Ms. Prange or Mr. Florin and any other person pursuant to which they were appointed as Directors of the Company, and there have been no transactions nor are there any proposed transactions between the Company and Ms. Prange or Mr. Florin that would require disclosure pursuant to Item 404(a) of Regulation S-K. Ms. Prange and Mr. Florin will receive compensation for their service as directors in accordance with the Company’s compensation policies for non-employee directors as described in the Company’s proxy materials for its 2019 Annual Meeting of Stockholders.
A copy of the press release announcing Ms. Prange’s and Mr. Florin’s appointment is furnished as Exhibit 99.1 and incorporated by reference in this Item 5.02.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
No. Description
99.1 Press Release dated December 4, 2019
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
| ATRICURE, INC. | |
|
|
|
|
Dated: | December 4, 2019 | By: | /s/ M. Andrew Wade |
|
|
| M. Andrew Wade |
|
|
| Senior Vice President and Chief Financial Officer |
|
Exhibit 99.1 |
December 4, 2019
AtriCure Names Two Industry Veterans to Board of Directors
MASON, Ohio--(BUSINESS WIRE) – December 4, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors.
Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein (Nasdaq: HSIC) and a member of the Executive Committee. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she led the Urology and Pelvic Health business for Boston Scientific, Inc. (NYSE: BSX) and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company (NYSE: JNJ). In addition to general management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies.
“I’m looking forward to joining the board of AtriCure and am in full support of their mission of reducing the global Afib epidemic and healing the lives of those affected,” said Ms. Prange. “I have met some terrific people and am excited about their strategy going forward.”
Mr. Florin is currently Executive Vice President at Zimmer Biomet Holdings (NYSE: ZBH), a global leader in musculoskeletal healthcare. He was appointed to this position in July 2019 upon announcing his intention to retire from the company. Previously, he served as Executive Vice President and Chief Financial Officer of the company. In addition, he served as Interim Chief Executive Officer of the company from July 2017 to December 2017. Prior to working at Zimmer Biomet Holdings, Mr. Florin was Chief Financial Officer for Biomet, Inc. until the company merged with Zimmer, Inc. and became Zimmer Biomet Holdings. Prior to working at Biomet, he held various roles at Boston Scientific, Inc., CR Bard, Inc. and Deloitte & Touche, LLP.
“I am truly excited to join the AtriCure board,” said Mr. Florin. “As I dug into this opportunity it became clear to me that AtriCure is having a significant positive impact on patients with Afib by providing their doctors new and improved ways to treat this disease and related complications. AtriCure is well positioned to capitalize on this significant opportunity.”
“I am pleased that Karen and Dan have agreed to join the AtriCure Board of Directors,” said Michael Carrel, President and Chief Executive Officer. “Their commercial and operating experience, along with their financial expertise will be incredibly beneficial to the management team as we continue our growth in the coming years. I am looking forward to working with and learning from both of them.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the
treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold left atrial appendage management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
CONTACTS:
Andy Wade
Investor Relations
Senior Vice President and Chief Financial Officer
(513) 755-4564
awade@AtriCure.com
Valerie Storch-Willhaus
Media Relations
Senior Director, Corporate Marketing and Communications
(612) 605-3311
vstorch-willhaus@AtriCure.com